Literature DB >> 16425102

Clinical characteristics and service utilization patterns of clients with schizophrenia-spectrum disorders in public residential detoxification settings.

Jennifer Alvidrez1, Barbara E Havassy.   

Abstract

Little is known about the treatment needs of clients found in residential detoxification programs who have comorbid schizophrenia-spectrum and substance use disorders. This study (N = 166) compares the service use patterns of comorbid detoxification clients with schizophrenia-spectrum disorders (CDT-S) to two other client groups: (1) comorbid detoxification clients with other mental health disorders (CDT-O), and (2) comorbid clients in residential mental health facilities with schizophrenia-spectrum disorders (CMH-S). Results show that CDT-S clients were much less likely to receive subsequent mental health treatment than CMH-S clients. Findings indicate that detoxification programs may be important settings in which to identify clients with schizophrenia who have unmet mental health treatment needs.

Entities:  

Mesh:

Year:  2006        PMID: 16425102     DOI: 10.1007/s10597-005-9020-9

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  25 in total

1.  Racial and ethnic differences in drug treatment entry of injection drug users in Massachusetts.

Authors:  L M Lundgren; M Amodeo; F Ferguson; K Davis
Journal:  J Subst Abuse Treat       Date:  2001-10

2.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

3.  Dual diagnosis subtypes in urban substance abuse and mental health clinics.

Authors:  D Hien; S Zimberg; S Weisman; M First; S Ackerman
Journal:  Psychiatr Serv       Date:  1997-08       Impact factor: 3.084

Review 4.  Co-occurring severe mental illness and substance use disorders: a review of recent research.

Authors:  J RachBeisel; J Scott; L Dixon
Journal:  Psychiatr Serv       Date:  1999-11       Impact factor: 3.084

Review 5.  Substance abuse among general psychiatric patients: place of presentation, diagnosis, and treatment.

Authors:  M Galanter; R Castaneda; J Ferman
Journal:  Am J Drug Alcohol Abuse       Date:  1988       Impact factor: 3.829

6.  Use of mental health and substance abuse treatment services by female injection drug users.

Authors:  Maryann Amodeo; Deborah Chassler; Faith Ferguson; Therese Fitzgerald; Lena Lundgren
Journal:  Am J Drug Alcohol Abuse       Date:  2004       Impact factor: 3.829

7.  Psychiatric comorbidity in methadone maintained patients.

Authors:  B J Mason; J H Kocsis; D Melia; E T Khuri; J Sweeney; A Wells; L Borg; R B Millman; M J Kreek
Journal:  J Addict Dis       Date:  1998

8.  The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services.

Authors:  D A Regier; W E Narrow; D S Rae; R W Manderscheid; B Z Locke; F K Goodwin
Journal:  Arch Gen Psychiatry       Date:  1993-02

9.  Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia.

Authors:  Andrew Shaner; Thad Eckman; Lisa J Roberts; Thomas Fuller
Journal:  Psychiatr Serv       Date:  2003-09       Impact factor: 3.084

10.  Linking alcohol- and drug-dependent adults to primary medical care: a randomized controlled trial of a multi-disciplinary health intervention in a detoxification unit.

Authors:  Jeffrey H Samet; Mary Jo Larson; Nicholas J Horton; Kathleen Doyle; Michael Winter; Richard Saitz
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

View more
  1 in total

1.  Factors associated with high use of general practitioner and psychiatrist services among patients attending an addiction rehabilitation center.

Authors:  Christophe Huỳnh; André Ngamini Ngui; Sylvia Kairouz; Alain Lesage; Marie-Josée Fleury
Journal:  BMC Psychiatry       Date:  2016-07-22       Impact factor: 3.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.